Document text
Principal Investigator: Helene D Benveniste
Organization: STATE UNIVERSITY NEW YORK STONY BROOK
Fiscal Year: 2020
Award: $463,521
Funding agency: National Institute on Aging
ABSTRACT
SARS-CoV-2 contact with the organism starts with binding to its key receptor ACE2 which is highly
expressed in the ciliated cells of the tracheal, bronchial, and nasal mucociliary epithelium. After binding,
the virus inhibits the cilia beating in the airways and suppresses mucociliary transport, the first line of
defense against invading microorganisms. Thus, augmenting the ciliary function may prevent the viral
infection at the very first steps or help fight the further propagation of the virus. ACE2 is also expressed
in selected brain cells, underlying the neurological effects of SARS-CoV-2.
The main objective of this supplement is to rapidly build a screening system, to identify drugs that can
be immediately applied for COVID-19 therapy, and to use the gained knowledge for expanding the
screen to a broader range of candidate compounds.
In our NIA supported grant we discovered the critical role of the nNOS-NO-cGC-cGMP signaling
pathway for ciliary activity in the brain and the airways. Here we describe our plans of targeting this
pathway with clinically-approved drugs in order to augment cilia activity and airways clearance. This
project can be later extended to build a sensitive and powerful drug screen for anti-COVID-19 therapy.
In our first Specific Aim we will develop a comprehensive computational toolbox and use it to
determine the key parameters (a signature) of the cilia activity in the airways’ and brain ciliated cells
from humans and humanized mouse model. In the second Specific Aim, we will apply our setup to
determine the signature of the cilia response to S1, the main cell binding ligand of SARS-CoV-2, and to
S1-expressing pseudotyped VSV-S1 virus. Finally, in our third Specific Aim we will examine anti-
SARS-CoV-2 drugs currently used in clinic and clinically-approved compounds that activate the NO-
cGMP pathway, as well as their combination to determine if such treatments can rescue the S1-affected
cilia activity in the airways and brain preparations. In the same set of experiments we will examine the
response of preparations from animals of different age, which may contribute to the profound old age-
bias of COVID-19. We emphasize that our selection of drugs to be tested is limited to the
therapeutically-approved compounds, thus enabling rapid translation of our findings into clinical
practice.
Terms: <2019 novel coronavirus><2019-nCoV><AD dementia><Acquired brain injury><Administrative Supplement><Affect><Age><Aging><Alzheimer><Alzheimer Type Dementia><Alzheimer disease><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer's><Alzheimer's Disease><Alzheimer's disease dementia><Alzheimers Dementia><Alzheimers disease><Animals><Award><Bacteria><Binding><Binding Proteins><Body Tissues><Brain><Brain Injuries><Brain Nervous System><Brain Ventricle><CNS lymphatic system><COVID-19><COVID19><Cell Body><Cells><Cerebral Ventricles><Cerebrospinal Fluid><Cilia><Clinic><Clinical><Cyclic GMP><Drug Screening><Drug usage><Drugs><Encephalon><Endogenous Nitrate Vasodilator><Endothelium-Derived Nitric Oxide><Epithelial><Epithelium><Epithelium Part><Funding><Goals><Grant><Guanosine Cyclic Monophosphate><Human><Infection><Invaded><Knowledge><Ligand Binding><Ligand Binding Protein><Ligand Binding Protein Gene><Ligands><Mediating><Medication><Methods><Modern Man><Molecular Interaction><Mononitrogen Monoxide><Mucociliary Clearance><Mucociliary Transport><Mucous body substance><Mucus><NIH><Nasal><Nasal Passages Nose><National Institutes of Health><Nervous System><Nervous system structure><Neurologic Body System><Neurologic Effect><Neurologic Organ System><Nitric Oxide><Nitrogen Monoxide><Nitrogen Protoxide><Nose><Organism><Pathway interactions><Pharmaceutic Preparations><Pharmaceutical Preparations><Physiologic><Physiological><Preparation><Preventative measure><Preventative therapy><Preventive measure><Preventive therapy><Primary Senile Degenerative Dementia><Process><Protein Binding><Receptor Protein><Respiratory System, Nose, Nasal Passages><Role><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Severe acute respiratory syndrome coronavirus 2><Signal Pathway><System><Techniques><Testing><Therapeutic><Therapeutic Uses><Time><Tissues><Trachea><Trachea Proper><Translations><United States National Institutes of Health><VSV><Vesicular Stomatitis Virus><Vesicular stomatitis Indiana virus><Viral><Viral Diseases><Virus><Virus Diseases><Wuhan coronavirus><aged brain><ages><aging brain><airway epithelium><analog><bound protein><brain cell><brain damage><brain lymph system><brain lymphatic system><brain-injured><cGMP><cerebral spinal fluid><clinical practice><corona virus disease 2019><coronavirus disease 2019><dementia of the Alzheimer type><drug candidate><drug detection><drug testing><drug use><drug/agent><endothelial cell derived relaxing factor><experiment><experimental research><experimental study><fighting><glia lymphatic circuit><glial lymphatic system><glialymphatic circuit><glialymphatic network><glialymphatic pathway><glialymphatic system><glymphatic pathway><glymphatic system><glymphatic-lymphatic system><glymphatics><humanized mice><humanized mouse><improved><living system><microorganism><mouse model><mucous><murine model><pathway><prevent><preventing><primary degenerative dementia><programs><receptor><receptor binding><receptor bound><response><screening><senile dementia of the Alzheimer type><social role><spinal fluid><therapeutic candidate><viral infection><virus infection><virus-induced disease><windpipe>